Image: Stock TitanConnect Biopharma Asthma Trial Reduces Failures 66%
• Connect Biopharma reported that its asthma trial reduced failures by 66% based on recent patient data. • Lung function improved by 250 mL by Day 7 compared to 120 mL for the placebo group among 160 patients. • These results impact the drug's regulatory approval and market potential because investors use FEV1, a measure of how much air a person can exhale, to judge if respiratory treatments work.
stocktitan.net